Want to see GERN full AI Analyst Report?
GERN Stock Chart & Stats
$1.55
$0.09(6.34%)
At close: 4:00 PM EDT
$1.55
$0.09(6.34%)
Day’s Range― - ―
52-Week Range$1.04 - $2.01
Previous CloseN/A
Volume230.62K
Average Volume (3M)10.67M
Market Cap
$867.34M
Enterprise Value$807.52
Total Cash (Recent Filing)$300.85M
Total Debt (Recent Filing)$122.14M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Nov 11, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding642,473,400
10 Day Avg. Volume10,204,094
30 Day Avg. Volume10,666,022
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)3.90
Price to Sales (P/S)4.79
P/FCF Ratio-7.92
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.33Price Target Upside179.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.02
Revenue Forecast (FY)$236.28M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue GrowthSustained revenue growth indicates increasing commercial adoption of RYTELO and expanding demand beyond an initial launch period. Management’s expectation of reaching the mid- to high-end of 2026 guidance supports continued product traction and a growing operating base over the next several quarters.
Expanding Prescribing FootprintGrowth in prescribing accounts broadens Geron’s commercial reach and creates a larger base from which patient utilization can develop. Earlier-line starts may also improve the product’s long-term market opportunity, supporting more durable revenue potential if adoption and treatment continuation persist.
Improving Operating LeverageRevenue growing materially faster than operating expenses is an important sign of improving operating leverage as commercialization scales. If this discipline continues, incremental sales could contribute more efficiently toward narrowing losses and funding Geron’s clinical pipeline without equivalent expense growth.
Bears Say
Persistent Cash Burn And LossesLarge operating and free-cash-flow deficits show that current commercial revenue is not yet sufficient to fund the business and its development programs. Continued burn can require external financing or balance-sheet resources, increasing dilution risk and limiting flexibility if profitability takes longer to achieve.
Rising Gross-to-net DeductionsHigher gross-to-net deductions reduce realized revenue per unit and can constrain the economic benefit of prescription growth. If deductions remain elevated as RYTELO scales, Geron may need stronger volume or cost control to translate commercial momentum into improved margins and cash generation.
Clinical And Regulatory UncertaintyPotential changes to the interim-analysis design introduce uncertainty around the timing and regulatory interpretation of IMpactMF results. Although the base-case final overall-survival analysis remains targeted for H2 2028, added complexity could delay clarity on the program’s expansion potential and future investment returns.
Geron News
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.04 and its highest was $2.01 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $867.34M.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Nov 11, 2026 which is in 57 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Aug 05, 2026. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.009 by -$0.011.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp does not currently pay dividends.
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is >-0.01.
How many shares outstanding does Geron Corp have?
Geron Corp has 642,473,400 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.009. Following the earnings report the stock price went up 21.642%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Geron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.33 (179.57% Upside)
$4.33 (179.57% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 19.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
2.27%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.52%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Geron Corp
Geron Corporation is an advanced-stage biopharmaceutical company dedicated to the creation and market introduction of treatments for myeloid blood cancers. Its primary drug candidate, imetelstat, is a telomerase inhibitor currently undergoing Phase 3 clinical evaluation. This therapy aims to suppress the unchecked proliferation of cancerous stem and progenitor cells characteristic of myeloid hematologic malignancies. Imetelstat is being developed to address low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. Established in 1990, Geron's corporate headquarters are located in Foster City, California.
GERN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.View all GERN earnings summariesGERN Stock 12 Month Forecast
Average Price Target
$4.33
▲(179.57% Upside)
Technical Analysis
Ownership Overview
0.06% Insiders
11.32% Mutual Funds
29.45% Other Institutional Investors
43.19% Public Companies and
Individual Investors